Department of Clinical pathology, South Egypt Cancer Institute, Assiut, Egypt.
Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
Pediatr Res. 2022 Apr;91(5):1203-1206. doi: 10.1038/s41390-021-01627-y. Epub 2021 Jun 18.
Regulatory T cells (Tregs) are linked to a reduction in alloreactive immune responses, but few studies have investigated the impact of hydroxyurea (HU) therapy on Tregs in sickle cell disease (SCD).
Our case-controlled study presented here included two groups, the first comprising 60 pediatric SCD patients, 30 of whom did not receive any treatment and 30 who received HU, and the second group consisting of 30 healthy controls. Flow cytometry was used to evaluate the percentage of CD4CD25Foxp3 Tregs present and their phenotypes.
The percentage of CD4CD25 Tregs was significantly increased in untreated SCD patients in comparison to treated SCD patients and controls. Conversely, treated SCD children had a lower percentage of CD4CD25 Tregs than controls. In addition, a significant increase in the percentage of CD4CD25Foxp3 Tregs was found in untreated SCD patients, compared to in HU-treated patients and controls. The percentage of naive CD45RA Tregs was significantly decreased in untreated SCD patients when compared to other groups.
Among children with SCD, HU treatment exhibited significant qualitative and quantitative effects on Tregs by decreasing their frequency, and increasing the proportion of naive CD45RA Tregs and reducing levels of the most suppressive Tregs: HLA-DR, CD39, and CD69.
Among children with, SCD, HU treatment exhibited significant qualitative and quantitative effects on Tregs. HU treatment in SCD decreases the frequency of Tregs, as well as the levels of the most suppressive Tregs: HLA-DR, CD39, and CD69. At the same time, HU increases the proportion of naive CD45RA Tregs. Our study showed the impact of HU therapy on Tregs in children with SCD.
调节性 T 细胞(Tregs)与减少同种反应性免疫反应有关,但很少有研究调查羟脲(HU)治疗对镰状细胞病(SCD)中 Tregs 的影响。
我们呈现的这项病例对照研究包括两组,第一组包括 60 名儿科 SCD 患者,其中 30 名未接受任何治疗,30 名接受 HU 治疗,第二组包括 30 名健康对照者。流式细胞术用于评估 CD4CD25Foxp3 Tregs 的存在比例及其表型。
与 HU 治疗的 SCD 患者和对照组相比,未经治疗的 SCD 患者中 CD4CD25 Tregs 的比例显著增加。相反,接受 HU 治疗的 SCD 患儿的 CD4CD25 Tregs 比例低于对照组。此外,与 HU 治疗的患者和对照组相比,未经治疗的 SCD 患者中 CD4CD25Foxp3 Tregs 的比例显著增加。与其他组相比,未经治疗的 SCD 患者中幼稚 CD45RA Tregs 的比例显著降低。
在 SCD 患儿中,HU 治疗通过降低其频率、增加幼稚 CD45RA Tregs 的比例以及降低最具抑制性的 Tregs:HLA-DR、CD39 和 CD69 的水平,对 Tregs 表现出显著的定性和定量影响。
在 SCD 患儿中,HU 治疗对 Tregs 具有显著的定性和定量影响。HU 治疗在 SCD 中降低 Tregs 的频率,以及最具抑制性的 Tregs:HLA-DR、CD39 和 CD69 的水平。同时,HU 增加了幼稚 CD45RA Tregs 的比例。我们的研究显示了 HU 治疗对 SCD 患儿 Tregs 的影响。